SINGAPORE, Jan. 18, 2026 (GLOBE NEWSWIRE) — Singapore-based OPay, a leading digital banking platform in emerging markets, has announced key management appointments as part of its new global strategic direction. The appointments took effect on December 1, 2025. The newly formed management team includes James Zhou as Executive Chairman, Lars Boilesen as Co-CEO, Stephen as […]

SINGAPORE, Jan. 18, 2026 (GLOBE NEWSWIRE) — OPay, a leader in emerging market digital banking headquartered in Singapore, has appointed Lars Boilesen as Co-CEO, effective December 1, 2025. As Co-CEO, Lars will be responsible for regulatory communication, business implementation, and strategic expansion in target markets, reporting to the OPay Board of Directors. Lars Boilesen brings

OPay Forms Global Core Management Team, Appoints Four Executives to Lead New Strategic Chapter GlobeNewswire January 19, 2026 SINGAPORE, Jan. 18, 2026 (GLOBE NEWSWIRE) — Singapore-based OPay, a leading digital banking platform in emerging markets, has announced key management appointments as part of its new global strategic direction. The appointments took effect on December 1,

OPay Appoints Tech Industry Leader Lars Boilesen as Co-CEO GlobeNewswire January 19, 2026 SINGAPORE, Jan. 18, 2026 (GLOBE NEWSWIRE) — OPay, a leader in emerging market digital banking headquartered in Singapore, has appointed Lars Boilesen as Co-CEO, effective December 1, 2025. As Co-CEO, Lars will be responsible for regulatory communication, business implementation, and strategic expansion

AbelZeta Pharma, Inc. (“AbelZeta”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, announced that AstraZeneca has agreed to acquire AbelZeta’s 50% share of the China development and commercialization rights to C-CAR031, such that AstraZeneca acquires the sole right to develop, manufacture and commercialize C-CAR031 globally.

(NYSE:FCN), HONG KONG, Jan. 18, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Speed Liu as a Senior Managing Director in the Business Transformation practice in Asia within the firm's Corporate Finance & Restructuring segment. Mr. Liu, who is based in Hong Kong, joins FTI Consulting with more than

Private Equity Expert Speed Liu Joins FTI Consulting in Hong Kong GlobeNewswire January 19, 2026 HONG KONG, Jan. 18, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Speed Liu as a Senior Managing Director in the Business Transformation practice in Asia within the firm's Corporate Finance & Restructuring segment.

Materials research generates vast amounts of data, but the information often exists in manufacturer-specific formats and the terminology is inconsistent, making it difficult to aggregate, compare, and reuse. Traditionally, researchers have had to spend considerable time on tedious tasks, such as format conversion, metadata assignment, and characteristics extraction. These extra steps can make researchers reluctant

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) (“Spruce”). Following this transaction, Harbour BioMed holds approximately 3.8% of

(AUST:MSB.AX),(NASDAQ:MESO), NEW YORK, Jan. 18, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided feedback received from the U.S. Food & Drug Administration (FDA) on potential filing of a Biologics License Application (BLA) for its allogeneic cell therapy product rexlemestrocel-L in patients with chronic discogenic